Loading…
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Increased oxidative stress is important in the pathogenesis of chronic obstructive pulmonary disease (COPD). We postulated that treatment with the antioxidant N-acetylcysteine would reduce the rate of lung-function decline, reduce yearly exacerbation rate, and improve outcomes. In a randomised place...
Saved in:
Published in: | The Lancet (British edition) 2005-04, Vol.365 (9470), p.1552-1560 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Increased oxidative stress is important in the pathogenesis of chronic obstructive pulmonary disease (COPD). We postulated that treatment with the antioxidant N-acetylcysteine would reduce the rate of lung-function decline, reduce yearly exacerbation rate, and improve outcomes.
In a randomised placebo-controlled study in 50 centres, 523 patients with COPD were randomly assigned to 600 mg daily N-acetylcysteine or placebo. Patients were followed for 3 years. Primary outcomes were yearly reduction in forced expiratory volume in 1 s (FEV
1) and the number of exacerbations per year. Analysis was by intention to treat.
The yearly rate of decline in FEV
1 did not differ between patients assigned N-acetylcysteine and those assigned placebo (54 mL [SE 6]
vs 47 mL [6]; difference in slope between groups 8 mL [9]; 95% CI −25 to 10). The number of exacerbations per year did not differ between groups (1·25 [SD 1·35]
vs 1·29 [SD 1·46]; hazard ratio 0·99 [95% CI 0·89–1·10, p=0·85]). Subgroup analysis suggested that the exacerbation rate might be reduced with N acetylcysteine in patients not treated with inhaled corticosteroids and secondary analysis was suggestive of an effect on hyperinflation.
N-acetylcysteine is ineffective at prevention of deterioration in lung function and prevention of exacerbations in patients with COPD. |
---|---|
ISSN: | 0140-6736 1474-547X |
DOI: | 10.1016/S0140-6736(05)66456-2 |